Constantino Michael T. 4
Research Summary
AI-generated summary
Humacyte (HUMA) Director Michael T. Constantino Buys 11,000 Shares
What Happened Michael T. Constantino, a director of Humacyte, Inc. (HUMA), purchased 11,000 shares of Humacyte common stock on May 18, 2026. The total reported cost was $9,840, based on a weighted average price of approximately $0.89 per share. The filing reports these purchases as open‑market acquisitions (transaction code P).
Key Details
- Transaction date: 2026-05-18; Filing date (Form 4): 2026-05-20 (timely; Form 4s are due within two business days).
- Shares acquired: 11,000 at a weighted average price of $0.89; total reported value $9,840.
- Price range (per footnote): individual trades executed between $0.8922 and $0.8958; weighted average reported as $0.89. The insider offered to provide exact per‑trade quantities/prices upon request.
- Shares owned after transaction: not specified in the provided filing excerpt.
- Transaction code: P = Purchase.
Context This was a straightforward open‑market purchase by a company director. Insider purchases are often watched by investors as a stronger signal than routine sales, but the filing does not state any motive. No derivative exercises, gifts, or tax‑withholding events were reported in this transaction.